109 related articles for article (PubMed ID: 25910237)
21. Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
Zuo M; Zheng YW; Lu SM; Li Y; Zhang SQ
Bioorg Med Chem; 2012 Jul; 20(14):4405-12. PubMed ID: 22698782
[TBL] [Abstract][Full Text] [Related]
22. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological activity of hydroxamic tertiary amines as histone deacetylase inhibitors.
Terracciano S; Chini MG; Riccio R; Bruno I; Bifulco G
ChemMedChem; 2012 Apr; 7(4):694-702. PubMed ID: 22278987
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
[TBL] [Abstract][Full Text] [Related]
26. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
27. [New synthesis of highly selective inhibitor of histone deacetylase 6--N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3b]indol-5-ylmethyl)benzamide--Tubastatin A].
Kozlov MV; Kleĭmenova AA; Konduktorov KA; Kochetkov SN
Bioorg Khim; 2013; 39(1):117-20. PubMed ID: 23844513
[TBL] [Abstract][Full Text] [Related]
28. Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
Meyners C; Wolff B; Kleinschek A; Krämer A; Meyer-Almes FJ
Bioorg Med Chem Lett; 2017 Apr; 27(7):1508-1512. PubMed ID: 28259626
[TBL] [Abstract][Full Text] [Related]
29. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies.
Kozikowski AP; Chen Y; Gaysin A; Chen B; D'Annibale MA; Suto CM; Langley BC
J Med Chem; 2007 Jun; 50(13):3054-61. PubMed ID: 17539623
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
[TBL] [Abstract][Full Text] [Related]
31. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
Zhou M; Ning C; Liu R; He Y; Yu N
Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
[TBL] [Abstract][Full Text] [Related]
33. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
Park H; Kim S; Kim YE; Lim SJ
ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
[TBL] [Abstract][Full Text] [Related]
34. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
[TBL] [Abstract][Full Text] [Related]
35. Real-time monitoring of conformational transitions of single-molecule histone deacetylase 8 with nanocircuits.
You S; Froberg J; Yu J; Haldar M; Sedigh A; Mallik S; Srivastava DK; Choi Y
Chem Commun (Camb); 2017 Mar; 53(23):3307-3310. PubMed ID: 28261707
[TBL] [Abstract][Full Text] [Related]
36. A miniaturized readout strategy for endogenous histone deacetylase activity.
Jost JO; Hanswillemenke A; Schwarzer D
Mol Biosyst; 2015 Jul; 11(7):1820-3. PubMed ID: 26009008
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2017 Dec; 9(18):2211-2237. PubMed ID: 29182018
[TBL] [Abstract][Full Text] [Related]
40. Tescalcin is a potential target of class I histone deacetylase inhibitors in neurons.
Takamatsu G; Katagiri C; Tomoyuki T; Shimizu-Okabe C; Nakamura W; Nakamura-Higa M; Hayakawa T; Wakabayashi S; Kondo T; Takayama C; Matsushita M
Biochem Biophys Res Commun; 2017 Jan; 482(4):1327-1333. PubMed ID: 27939885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
